A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

Exclusion Criteria

• •1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
• •2. Individuals with any progressive or severe neurological disorder, seizure disorder or previous Guillain-Barré syndrome.
• •3. Individuals who, in the judgment of the investigator, may not be able to comply with all the required study procedures.
• •4. Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
• •5. Individuals with history of reactive arthritis.
• •6. Individuals with known HIV or hepatitis B virus infection or HIV related disease, history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system. Individuals under systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to screening.
• •7. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
• •8. Individuals with a neutrophil count lower than 1.8 x 10\^9/L (applicable to the initial 18 subjects) or lower than 1.0 x 10\^9/L (applicable to the additional subjects if approved by DSMB) at screening
• •9. Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, Type 2 diabetes mellitus, hypertension, cardiac, renal or hepatic disease and tuberculosis).
• •10. Individuals who have any malignancy or lymphoproliferative disorder.
• •11. Individuals with history of allergy to vaccines components or any other allergies deemed by the investigator to increase the risk of an adverse event if they were to participate in the trial.
• •12. Individuals participating in any clinical trial with another investigational product within 28 days prior to the screening study visit or intent to participate in another clinical study at any time during the conduct of this study.
• •13. Individuals who received vaccines containing meningococcal A, C, W, Y or tetanus, diphtheria or pertussis antigens within 12 months before screening, or any other vaccines within 4 weeks prior to screening in this study or who are planning to receive any vaccine within the entire study duration.
• •14. Individuals who have received blood, blood products, and/or plasma derivatives including parenteral immunoglobulin preparations in the 12 weeks prior to the first dose of the study vaccine.
• •15. Individuals who are study personnel or immediate family members (parents, children, spouse and brothers/sisters) to the personnel conducting this study.
• •16. Individuals with body temperature \> 38.0°C within 3 days of intended study vaccination is a reason for delay of vaccination
• •17. Individuals with Body Mass Index (BMI)\> 30 kg/m\^2
• •18. Individuals with history of substance or alcohol abuse within the past 2 years.
• •19. Women who are pregnant or are breast-feeding, or are of childbearing age who have not used (for the two months preceding the 1st vaccination) and are not willing to use acceptable contraceptive measures, for the duration of the study. If subjects are women of childbearing potential, they must have a negative pregnancy test at screening visit and prior to enrollment (visit 1). For the purposes of this study acceptable methods of contraception are oral, injected or implantable contraceptives.
• •20. Individuals who have a previously laboratory confirmed case of disease caused by S. sonnei.
• •21. Any condition which, in the opinion of the investigator, may pose an increased and unreasonable safety risk to the subject if they participated in the study.
• •22. Individuals with a previous history of Benign Ethnic Neutropenia or drug related neutropenia.
• •23. Individuals who have or are likely to require concomitant treatment with neutropenic agents.